Fibronostics’ Post

2024 FGS Annual Meeting Starts Today! We are thrilled to be at the 2024 FGS Annual Meeting, happening today and tomorrow, September 6-7, 2024, at the Hilton in Orlando, Florida. Visit us at booth 21 to meet our President, Sven Henrichwark, and CEO, Brock Smith, and learn more about our innovative product, LIVERFASt. Whether you're interested in discussing potential collaborations or simply networking with healthcare professionals, we are excited to connect with you. Don't miss this chance to explore new opportunities and advance healthcare with us! #FGS2024 #LIVERFASt #Fibroconference #MeetOurTeam

The Annual Florida Gastroenterologic Society (FGS) Meeting is only a few days away! Come down to the Hilton Orlando Lake Buena Vista in the Disney Springs Area from the 6th to the 8th of September and meet our amazing team who will be representing Fibronostics! Come meet us at Booth 21 to discuss more about our exciting research and innovative solutions for liver screening! We hope to see you there! #FGS2024 #LIVERFASt #Fibroconference #MeetOurTeam

Happy 67th Independence Day, Malaysia! Today, we celebrate with our friends and partners in Malaysia as they mark 67 years of independence. As close neighbors, Singapore and Malaysia share a deep bond and a history of collaboration and friendship. Wishing Malaysia continued peace, progress, and prosperity. Selamat Hari Merdeka!

Exciting News from Fibronostics! We are proud to announce that LIVERSTAT, our innovative software as medical device (SaMD) designed to aid clinicians in the management of suspected liver disease, has been listed as a Class A Medical Device by the Medical Device Authority (MDA) of Malaysia! Achieving the regulatory approval is a testament to our commitment to delivering high-quality, reliable, and impactful healthcare solutions. Why is this important for us and our partners? 1️⃣ Broader Market Reach: Regulatory approvals in multiple countries open doors to new markets, allowing us to bring our innovative solutions to more clinicians and patients around the world. 2️⃣ Enhanced Credibility: Each regulatory approval reinforces the trust and confidence that healthcare professionals and partners place in our technology, ensuring that we meet stringent safety and quality standards. 3️⃣ Collaboration Opportunities: As we expand into new regions, we look forward to forging new partnerships and strengthening existing ones, all with the shared goal of improving liver disease management globally. 4️⃣ Positive Patient Impact: Ultimately, our mission is to enhance patient outcomes. These approvals are crucial steps towards ensuring that more patients benefit from advanced, data-driven tools like LIVERSTAT. We extend our deepest gratitude to the Fibronostics team for their relentless efforts and to our partners for their unwavering support. We are excited about the journey ahead as we pursue additional regulatory approvals in more countries, aiming to make a global impact in liver disease management. Thank you for being part of this exciting journey with us! #LIVERSTAT #RegulatoryApproval #GlobalHealth #FibronosticsTeam

Fibronostics is expanding! Thrilled to announce that we are hiring Liver Health Specialists (Sales) in key US markets. We are an early stage, global diagnostics company with a culture that is conducive to both personal and professional growth in a very dynamic, exciting healthcare market. Join a world-class team with near-term advancement opportunities, excellent comp plan, and full benefits. Diagnostic experience a plus but not necessary, as are current relationships in Hepatology, Gastroenterology, Endocrinology, and Primary Care Physicians. TN, TX, S FL, GA, AZ, KY. Please email us at careers@Fibronostics.com if interested.

How often should you get your blood tested? Many organizations, such as the NHS (2023), recommend everyone over the age of 40 to go for a health check-up at least once a year, to screen for any possible health concerns. Some organizations, like the U.S. Preventative Services Task Force (2023), recommends that people who are obese, regardless of age, should get their blood tested every three years, to monitor their blood glucose levels and to also check their overall metabolic health.   Physical examinations are crucial for maintaining overall health and addressing any lingering concerns with your healthcare provider. They offer a chance to discuss minor health issues, establish a relationship with your primary care provider, and receive early detection of chronic diseases like heart disease or diabetes. This proactive approach helps in managing health effectively and making lifestyle adjustments to prevent future issues. Even if you’re currently healthy, having a provider who knows your history is valuable for timely care when problems arise (Cleveland Clinic, 2023).   LIVERFASt™ utilizes 10 common blood biomarkers that can be found in a typical blood test result sheet. LIVERFASt™ is a noninvasive test to provide staging of fibrosis, activity, and steatosis in individuals diagnosed with MASLD and MASH.   Using advanced analytics, LIVERFASt™ can provide a risk stratification on the condition of your liver, to better aid you and your healthcare physician make decisions in managing your metabolic health.   Ask your doctor about LIVERFASt™ today!

Calling back to one of the posters we presented during the most recent combined GiHep and Singapore Hepatology Conference (SHC), titled: 'Application of LIVERFASt™ to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome', where we explored the prognostic values of LIVERFASt™ as a noninvasive screening tool, to detect hepatic steatosis in chronic Hepatitis B (HBV), and to identify patients with chronic HBV that have co-existing metabolic-dysfunction associated steatotic liver disease (MASLD). Our study, originally conducted in 2023, revealed that there was significant correlation between the Fibroscan Controlled Attenuation Parameter (CAP) scores and LIVERFASt™ steatosis scores. This shows that LIVERFASt™ can act as an effective screening tool for detecting steatosis among patients with different co-morbidities, including chronic HBV. In conclusion, LIVERFASt™ is a powerful noninvasive tool for screening liver steatosis in chronic Hepatitis B patients. Its significant correlation with Fibroscan CAP scores shows it has the ability to enhance early detection and aid in the management of liver steatosis, benefiting patient care. To view our study, visit the link here: https://lnkd.in/gukhKsBC #SHC2024 #LiverHealth #Fibronostics #LIVERFASt #Steatosis

Our recent study revealed that combining LIVERSTAT, a supplement in clinical management for suspected liver disease, with Fibroscan (LSM) significantly outperforms the traditional FIB-4 and LSM combination in detecting advanced fibrosis (F3F4) in MASLD patients.   Key Highlights: * Double the Detection: Identified twice as many F3F4 patients as FIB-4 + Fibroscan. * No Grey Zones: Avoids the risk of missing cases due to "grey zones". * Improved Accuracy: Helps catch 41% of F3F4 cases missed by FIB-4. LIVERSTAT is revolutionizing early detection, specialist referrals, assessment in primary care and allowing more time for prevention. It’s setting a new standard for more effective liver disease management by both general practitioners and specialists.    #LIVERSTAT #SHC2024 #LiverHealth #MASLD